Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397214 | 0.85 | APOBEC3G (0.37) | MEN1ALDH1A1KMT2ACA2CA9 | |
| SCHEMBL64494 | 0.85 | CA2 (0.43) | MEN1ALDH1A1KMT2AMLYCDCA1 | |
| SCHEMBL15082546 | 0.81 | ALDH1A1 (0.37) | MEN1ALDH1A1KMT2AMLYCDCA1 | |
| SCHEMBL624941 | 0.78 | KMT2A (0.38) | MEN1ALDH1A1KMT2AMLYCDCA1 | |
| SCHEMBL28783484 | 0.76 | MLYCD (0.35) | MEN1ALDH1A1KMT2AMLYCDCA1 | |
| SCHEMBL10059165 | 0.75 | HSP90AA1 (0.36) | MEN1ALDH1A1KMT2ACA1CA2 | |
| SCHEMBL29279172 | 0.74 | ALDH1A1 (0.33) | MEN1ALDH1A1KMT2ACA1CA2 | |
| SCHEMBL6191256 | 0.74 | GRM2 (0.39) | MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL28384073 | 0.74 | CA2 (0.35) | MEN1ALDH1A1KMT2ACA1CA2 | |
| SCHEMBL7937074 | 0.73 | ALDH1A1 (0.37) | MEN1ALDH1A1KMT2AMLYCDCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | MEN1 4606/4885ALDH1A1 259/4885KMT2A 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.